WEBINAR: Tuesday 16 February, 7.30 - 8.45 pm
The future is here! PHARMAC have made a decision to fully fund empaglifozin and dulaglutide (pending Medsafe approval) from February 2021 under special authority. What does this mean for type two diabetes management going forward?
Endocrinologist Dr Ryan Paul and RNZCGP Medical Director Dr Bryan Betty discuss the role of these medications in diabetic treatment, guidance on the updated special authority criteria and best practice prescribing.
This webinar will consider a pragmatic approach to use in primary care with a focus on how we can target our vulnerable community to improve health outcomes.
Questions are welcome and we will endeavour to get through as many as possible during the time available.
Click the link to register: https://www.goodfellowunit.org/node/768108
Diabetes Nurse Hauraki PHO